Abu Dhabi Launches Non-Invasive Liquid Biopsy for Colorectal Cancer Screening

The Abu Dhabi Public Health Centre (ADPHC), in collaboration with healthcare leader M42, has introduced a cutting-edge liquid biopsy test for colorectal cancer. The non-invasive, blood-based screening tool is part of efforts to enhance early detection and risk assessment of colorectal cancer in the UAE capital.

The liquid biopsy, though a vital advancement, does not replace colonoscopy—the gold standard for colorectal cancer diagnosis. Instead, it serves as a complementary tool for identifying tumours or precancerous growths in the colon, facilitating earlier and less invasive screening. The service will be available through the Ifhas comprehensive health screening programme at Ambulatory Healthcare Services (AHS) and M42 facilities across Abu Dhabi, Al Ain, and the Al Dhafra region.

“Abu Dhabi is taking a crucial step in prioritizing community health by promoting early cancer detection,” said Dr. Ahmed AlKhazraji, Acting Director General of ADPHC. “The introduction of an innovative and non-invasive test like liquid biopsy provides a more accessible and comfortable screening option for patients, reducing barriers and encouraging greater participation in regular screenings.”

Dr. Fahed Al Marzooqi, Deputy COO of M42, emphasized the test’s potential to address one of the leading causes of cancer-related deaths. “This step will help boost early detection for colorectal cancer in Abu Dhabi. By offering a more accessible and non-invasive screening method, we aim to increase participation rates and improve outcomes, ultimately supporting a healthier future for the people of the UAE,” he stated.

Colorectal cancer remains the third most prevalent cancer type in Abu Dhabi, with men showing a higher incidence rate. According to 2023 data, 67% of new colorectal cancer cases in the emirate were diagnosed at a late stage, significantly impacting survival rates and health outcomes.

Routine screening is a key strategy for improving survival rates, with the Department of Health in Abu Dhabi recommending colorectal cancer screenings for all men and women over the age of 40. The introduction of the liquid biopsy test is expected to remove some of the barriers to screening, such as patient discomfort, thereby encouraging higher participation rates.

This initiative aligns with Abu Dhabi’s broader healthcare strategy to adopt innovative solutions that improve public health outcomes. By incorporating advanced technology like liquid biopsy into its screening programmes, the emirate underscores its commitment to early detection and proactive health management.

The new test represents a significant step in the fight against colorectal cancer, offering a more comfortable and accessible pathway to better health for residents across the UAE.